Manipulation of rapid eye movement sleep via orexin and GABAA receptor modulators differentially affects fear extinction in mice: effect of stable versus disrupted circadian rhythm.

GABAA receptor positive allosteric modulator REM sleep circadian disruption fear extinction orexin receptor antagonists posttraumatic stress disorder

Journal

Sleep
ISSN: 1550-9109
Titre abrégé: Sleep
Pays: United States
ID NLM: 7809084

Informations de publication

Date de publication:
13 09 2021
Historique:
received: 02 09 2020
revised: 22 01 2021
pubmed: 16 3 2021
medline: 30 10 2021
entrez: 15 3 2021
Statut: ppublish

Résumé

Sleep disruption, and especially rapid eye movement (REM) sleep disruption, is associated with fear inhibition impairment in animals and humans. The REM sleep-fear inhibition relationship raises concern for individuals with posttraumatic stress disorder (PTSD), whose sleep disturbance is commonly treated with hypnotics that disrupt and/or decrease REM sleep, such as benzodiazepines or "Z-drugs." Here, we examined the effects of the Z-drug zolpidem, a gamma-aminobutyric acidA (GABAA) receptor positive allosteric modulator, as well as suvorexant, an orexin receptor antagonist (hypnotics which decrease and increase REM sleep, respectively) in the context of circadian disruption in murine models of fear inhibition-related processes (i.e. fear extinction and safety learning). Adult male C57Bl/6J mice completed fear and safety conditioning before undergoing shifts in the light-dark (LD) cycle or maintaining a consistent LD schedule. Fear extinction and recall of conditioned safety were thereafter tested daily. Immediately prior to the onset of the light phase between testing sessions, mice were treated with zolpidem, suvorexant, or vehicle (methylcellulose). Polysomnographic analyses showed the temporal distribution of REM sleep was misaligned during LD cycle-shifts, while REM sleep duration was preserved. Suvorexant increased REM sleep and improved fear extinction rate, relative to zolpidem, which decreased REM sleep. Survival analysis demonstrated LD shifted mice treated with suvorexant were faster to achieve complete extinction than vehicle and zolpidem-treated mice in the LD shifted condition. By contrast, retention of conditioned safety memory was not influenced by either treatment. This study thus provides preclinical evidence for the potential clinical utility of hypnotics which increase REM sleep for fear extinction after PTSD-relevant sleep disturbance.

Identifiants

pubmed: 33720375
pii: 6171207
doi: 10.1093/sleep/zsab068
pii:
doi:

Substances chimiques

Orexins 0
Receptors, GABA-A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Jacob W Clark (JW)

School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, VIC, Australia.
Department of Pharmacology and Therapeutics, The University of Melbourne, VIC, Australia.
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia.

Heather Daykin (H)

Department of Pharmacology and Therapeutics, The University of Melbourne, VIC, Australia.
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia.

Jeremy A Metha (JA)

Department of Pharmacology and Therapeutics, The University of Melbourne, VIC, Australia.
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia.
Brain, Mind and Markets Laboratory, Department of Finance, The University of Melbourne, VIC, Australia.

Giancarlo Allocca (G)

Department of Pharmacology and Therapeutics, The University of Melbourne, VIC, Australia.
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia.
Somnivore Pty. Ltd., Bacchus Marsh, VIC, Australia.

Daniel Hoyer (D)

Department of Pharmacology and Therapeutics, The University of Melbourne, VIC, Australia.
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia.
Department of Molecular Medicine, The Scripps Research Institute, CA, USA.

Sean P A Drummond (SPA)

School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, VIC, Australia.

Laura H Jacobson (LH)

Department of Pharmacology and Therapeutics, The University of Melbourne, VIC, Australia.
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH